Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1138684 | 1.00 | CYP2C19 (0.55) | CYP2C19HIF1ACYP1A2CYP2D6KMT2A | |
| SCHEMBL1143912 | 1.00 | CYP2C19 (0.55) | CYP2C19HIF1ACYP1A2CYP2D6KMT2A | |
| Hydrochloric Acid SCHEMBL350882 | 0.98 | CYP2C19 (0.53) | CYP2C19HIF1ACYP1A2CYP2D6KMT2A | |
| Hydrochloric Acid SCHEMBL8538776 | 0.98 | CYP2C19 (0.53) | CYP2C19HIF1ACYP1A2CYP2D6KMT2A | |
| Hydrochloric Acid SCHEMBL1144491 | 0.98 | CYP2C19 (0.53) | CYP2C19HIF1ACYP1A2CYP2D6KMT2A | |
| SCHEMBL1139107 | 0.87 | CYP2C19 (0.53) | CYP2C19HIF1ACYP1A2CYP2D6KMT2A | |
| SCHEMBL1139315 | 0.87 | CYP2C19 (0.53) | CYP2C19HIF1ACYP1A2CYP2D6KMT2A | |
| SCHEMBL6539846 | 0.85 | ESR1 (0.47) | CYP2C19HIF1ACYP1A2KMT2AMIF | |
| SCHEMBL830225 | 0.85 | MIF (0.59) | CYP2C19HIF1ACYP1A2CYP2D6KMT2A | |
| SCHEMBL1138666 | 0.85 | MIF (0.42) | CYP2C19HIF1ACYP1A2KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110802-B1 | ETHYNYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-10-10 | — | — | EP | disclosed |
| US-9725416-B2 | Ethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3110802-A1 | ETHYNYL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-01-04 | — | — | EP | disclosed |
| US-20160362383-A1 | ETHYNYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-12-15 | — | — | US | disclosed |
| WO-2015128307-A1 | ETHYNYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-03 | — | — | WO | disclosed |
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | disclosed |
| EP-1828144-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | disclosed |
| WO-2006053342-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| CN-1751037-A | Sulfonamide derivatives as PPAR modulators | LILLY CO ELI (US) | 2006-03-22 | — | — | CN | disclosed |
| US-20040023344-A1 | Method for producing an optically activ beta-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1228083-A2 | THERAPEUTIC TREATMENT OF ANDROGEN RECEPTOR DRIVEN CONDITIONS | Hollis-Eden Pharmaceuticals Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001023405-A2 | THERAPEUTIC TREATMENT OF ANDROGEN RECEPTOR DRIVEN CONDITIONS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-0946588-A1 | USE OF DIPEPTIDE DERIVATIVES | Astra Aktiebolag (publ) (SE) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028327-A1 | NEW USE OF DIPEPTIDE DERIVATIVES | ASTRA AKTIEBOLAG (PUBL) (SE) | 1998-07-02 | — | — | WO | disclosed |
| WO-1995006038-A1 | PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1995-03-02 | — | — | WO | disclosed |
| EP-0057444-B1 | DICHLOROAMINO ACID DERIVATIVES USEFUL AS POTENT GERMICIDAL AND FUNGICIDAL AGENTS | MERCK & CO. INC. (US) | 1986-05-07 | — | — | EP | disclosed |
| US-4386103-A | ENVIRONMENT, FOOD TREATMENT, PERSONAL OR VETERINARY HYGIENE | MERCK & CO., INC. (US) | 1983-05-31 | — | — | US | disclosed |
| EP-0057444-A2 | Dichloroamino acid derivatives useful as potent germicidal and fungicidal agents | MERCK & CO. INC. (US) | 1982-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362383-A1 | ETHYNYL DERIVATIVES | GRIA4, GRM4, GRM2 | CYP2C19 3251/4885HIF1A 1453/4885CYP1A2 3471/4885 |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | CYP2C19 4551/4885HIF1A 537/4885CYP1A2 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.